CAESAREA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results

A survey commissioned by Itamar Medical found that a third of respondents were unaware that treating sleep apnea can significantly reduce the health risks associated with cardiovascular disease, diabetes, and stroke ATLANTA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- According to a survey commissioned by

CAESAREA, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the company will

CAESAREA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep

CAESAREA, Israel, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep

CAESAREA, Israel , Feb. 04, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, February 4th by Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), please note that the contact information was incorrect. The corrected release follows: Itamar Medical Ltd.

CAESAREA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Scott P.

Enables Itamar to leverage Spry’s existing FDA-cleared technology to bring to market the first device for continuous remote patient monitoring (RPM) of sleep apnea Adds the capability to monitor the longer-term accumulated disease burden of sleep apnea to complement the single night diagnostics

- 2020 Fourth Quarter Revenues Expected to Increase More Than 28% to $12.5-$12.8 million - - 2020 Fiscal Year Revenues Expected to Increase Approximately 31% to $40.8-$41.1 million - CAESAREA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd.